We have located links that may give you full text access.
COMMENT
JOURNAL ARTICLE
Tubulin-targeting agent combination therapies: dosing schedule could matter.
British Journal of Pharmacology 2013 April
UNLABELLED: Tubulin-binding agents are potent cytotoxic drugs that are largely used to treat haematological malignancies and solid tumours. In this issue of British Journal of Pharmacology, doxorubicin was shown to decrease the activity of vincristine when administered simultaneously, unless cell cycle arrest mechanisms were disrupted. This observation emphasizes the need to better explore schedule-dependent antagonist effects in anticancer drug combination therapies.
LINKED ARTICLE: This article is a commentary on the research paper by Ehrhardt et al., pp. 1558-1569 of this issue. To view this paper visit https://dx.doi.org/10.1111/bph.12068.
LINKED ARTICLE: This article is a commentary on the research paper by Ehrhardt et al., pp. 1558-1569 of this issue. To view this paper visit https://dx.doi.org/10.1111/bph.12068.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app